Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
67Cu-SARTATE in pediatric high-risk neuroblastoma
NCT04023331Phase 2Terminated
- Sponsor
- Clarity Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- Jan 2025
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of 67Cu-SARTATE in neuroblastoma, sponsored by Clarity Pharmaceuticals. Started Aug 2020; status: terminated.
02
Drugs
67Cu-SARTATE
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04023331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023331.